Shanghai Shen Lian Biomedical Corporation (SHA:688098)
China · Delayed Price · Currency is CNY 8.27
-0.13 (-1.55%)
Sep 2, 2026, 3:00 PM CST
SHA:688098 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,421 | 3,647 | 2,246 | 3,072 | 3,261 | 4,534 | |
Market Cap Growth | -32.71% | 62.34% | -26.87% | -5.79% | -28.08% | -31.23% |
Enterprise Value | 3,417 | 3,538 | 2,097 | 2,909 | 2,931 | 4,093 |
Last Close Price | 8.40 | 8.88 | 5.47 | 7.42 | 7.79 | 10.72 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 97.45 | 53.36 | 41.14 |
Forward PE | - | 24.74 | 24.74 | 27.70 | - | - |
PS Ratio | 12.28 | 12.65 | 7.40 | 10.19 | 9.92 | 12.65 |
PB Ratio | 2.45 | 2.61 | 1.58 | 2.04 | 2.18 | 3.08 |
P/TBV Ratio | 2.71 | 2.88 | 1.72 | 2.20 | 2.26 | 3.14 |
P/FCF Ratio | - | - | 504.58 | - | - | - |
P/OCF Ratio | 438.45 | 110.24 | 25.14 | 871.25 | 358.76 | 50.31 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.27 | 12.27 | 6.91 | 9.65 | 8.92 | 11.42 |
EV/EBITDA Ratio | 57.52 | 78.47 | 60.92 | 32.02 | 23.54 | 26.59 |
EV/EBIT Ratio | - | - | - | 105.02 | 43.38 | 37.11 |
EV/FCF Ratio | - | - | 471.14 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.01 | 0.01 | 0.00 | 0 | 0 |
Debt / EBITDA Ratio | 0.90 | 0.31 | 0.44 | 0.01 | 0.00 | 0.00 |
Debt / FCF Ratio | - | - | 3.48 | - | - | - |
Net Debt / Equity Ratio | -0.01 | -0.10 | -0.12 | -0.14 | -0.24 | -0.32 |
Net Debt / EBITDA Ratio | -0.21 | -3.12 | -5.07 | -2.27 | -2.87 | -3.04 |
Net Debt / FCF Ratio | 0.41 | 11.57 | -39.21 | 1.63 | 4.25 | 4.77 |
Asset Turnover | 0.18 | 0.19 | 0.19 | 0.19 | 0.21 | 0.23 |
Inventory Turnover | 1.14 | 1.31 | 1.17 | 0.77 | 0.74 | 1.00 |
Quick Ratio | 2.68 | 3.30 | 3.91 | 6.33 | 6.04 | 5.54 |
Current Ratio | 3.54 | 4.02 | 4.74 | 7.82 | 7.26 | 6.46 |
Return on Equity (ROE) | -2.16% | -1.77% | -3.32% | 1.99% | 4.11% | 7.28% |
Return on Assets (ROA) | -0.93% | -1.20% | -1.34% | 1.08% | 2.64% | 4.43% |
Return on Invested Capital (ROIC) | -1.69% | -2.37% | -2.64% | 1.87% | 5.15% | 10.08% |
Return on Capital Employed (ROCE) | -1.60% | -2.10% | -2.30% | 1.80% | 4.50% | 7.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.78% | -0.56% | -1.99% | 1.03% | 1.87% | 2.43% |
FCF Yield | -0.86% | -0.33% | 0.20% | -4.11% | -2.58% | -2.16% |
Dividend Yield | - | - | - | 0.47% | 1.03% | - |
Payout Ratio | - | - | - | 103.98% | 60.25% | 37.03% |
Buyback Yield / Dilution | 4.61% | -0.78% | -3.23% | 3.28% | 0.20% | 2.31% |
Total Shareholder Return | 4.61% | -0.78% | -3.23% | 3.75% | 1.23% | 2.31% |